Scioderm — Morgenthaler

Scioderm is focused on the development of innovative drugs for the treatment of chronic diseases of the skin.

Acquired by Amicus

Links to other Web sites found here are provided to assist you in locating information. Morgenthaler is not responsible for the content of the Web sites found at these links, or beyond, and does not attest to the accuracy, completeness or timeliness of the information they contain. In addition, we have highlighted a select number portfolio companies on a number of our Web pages, but encourage you to review our entire portfolio listed in our Portfolio tabs.

Recent Comments

Archives

Categories

Meta